The oncofetal protein IMP3: a novel grading tool and predictor of poor clinical outcome in human gliomas
| Autor: | Valentina Vaira, Andrea Di Cristofori, Stefano Ferrero, Paolo Rampini, Alessandro Del Gobbo, Carlo Patriarca, Silvano Bosari, Lucia Ferrari, Dario Ricca, Manuela Caroli |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Pathology IDH1 Proliferation index Article Subject lcsh:Medicine Kaplan-Meier Estimate Biology behavioral disciplines and activities General Biochemistry Genetics and Molecular Biology Disease-Free Survival Young Adult Text mining Antigens Neoplasm Internal medicine Glioma medicine Biomarkers Tumor Humans Young adult Grading (tumors) neoplasms Aged General Immunology and Microbiology business.industry lcsh:R RNA-Binding Proteins General Medicine Middle Aged medicine.disease Prognosis Phenotype Who guidelines Mutation Female Neoplasm Recurrence Local business Research Article |
| Zdroj: | BioMed Research International BioMed Research International, Vol 2015 (2015) |
| ISSN: | 2314-6141 |
| Popis: | Morphologic criteria illustrated in WHO guidelines are the most significant prognostic factor in human gliomas, but novel biomarkers are needed to identify patients with a poorer outcome. The present study examined the expression of the oncofetal protein IMP3 in a series of 135 patients affected by high-grade (grade III and IV) gliomas, correlating the results with proliferative activity, molecular parameters, and clinical and follow-up data. Overall, IMP3 expression was higher in glioblastomas (68%) than in grade III tumors (20%,P<0.0001), and IMP3-positive high-grade gliomas showed a shorter overall and disease-free survival than negative ones (P=0.0002andP=0.006, resp.). IMP3 expression was significantly associated with the absence of mutations of IDH1 gene (P=0.0001) and with the unmethylated phenotype of MGMT in high-grade gliomas (P=0.004). High Ki67 levels were correlated with better prognosis in glioblastomas but IMP3 expression was not correlated with the proliferation index. These findings confirm the role of IMP3 as a marker of poor outcome, also in consideration of its association with IDH1 wild-type phenotype and MGMT unmethylated status. The data suggest that IMP3 staining could identify a subgroup of patients with poor prognosis and at risk of recurrence in high-grade gliomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text